GSK won US accelerated approval on Tuesday for Nelkarmi, a once-daily oral medicine for a rare form of advanced lung cancer, delivering the second drug to clear the Food and Drug Administration from the $10.6 billion acquisition of Nuvalent completed in July.
The FDA cleared neladalkib, sold as Nelkarmi, for adults with locally advanced or metastatic non-small cell lung cancer carrying the anaplastic lymphoma kinase, or ALK, mutation. Eligible patients must have already received an ALK tyrosine kinase inhibitor called alectinib, or two or more prior ALK inhibitors plus platinum-based chemotherapy, according to the agency said.
That eligibility rule is the story's clinical heart. These patients have already burned through the standard targeted therapies, and until now chemotherapy was often the main remaining option, Reuters reported.

The approval also completes a striking corporate turnaround. GSK exited oncology a decade ago; chief executive Luke Miels has led its return, and the $10.6 billion Nuvalent purchase is the company’s most aggressive move back into the field, Reuters reported.
Nelkarmi treats progressed ALK-positive lung cancer
- Nelkarmi is a daily pill for ALK-positive lung cancer that has progressed after earlier ALK-targeted drugs — not a first treatment, and not for other cancer types.
- The approval is “accelerated,” meaning it rests on early evidence of tumor shrinkage; a larger trial proving the drug extends survival or delays progression is still running.
- It comes from the same $10.6 billion deal that produced Jideytro, approved in July for ROS1-positive lung cancer — a parallel genetic subtype treated with a similar logic.
How the FDA justified accelerated approval
Accelerated approval is a regulatory pathway the FDA uses when a drug for a serious condition shows an effect on a surrogate measure — here, tumor shrinkage — likely to predict real benefit, before confirmatory trials finish. Bloomberg’s account notes the agency acted because an early-stage trial found notable anti-cancer effects and a safety profile resembling existing ALK-targeted drugs.
The application’s foundation matters clinically. Nuvalent’s trial showed the drug shrank tumors, including ones that had spread to the brain, in patients previously treated with ALK-targeted drugs, Reuters reported. Brain metastases are a defining challenge in ALK-positive disease, so any agent with intracranial activity addresses a specific unmet need.
GSK scores FDA approval for Nelkarmi, its 2nd lung cancer drug from Nuvalent deal https://t.co/4c5gpYQ8vE
But the mechanism of action — in plain English, how the molecule actually works inside cells — is targeted, not broad. Kinase inhibitors fit into the faulty signaling protein produced by the ALK gene rearrangement, stalling the growth signal that tumor cells depend on. They do not work in cancers lacking that driver mutation.
GSK builds oncology lung cancer franchise
GSK’s oncology business is being rebuilt around lung cancer first. Two of the two marketed drugs from the Nuvalent deal are lung cancer medicines: Jideytro, approved July 22 for ROS1-positive non-small cell lung cancer after a prior ROS1 inhibitor, and now Nelkarmi.
“I think we’re making great progress with the oncology portfolio,” said Hesham Abdullah, GSK’s head of oncology R&D, in a briefing, according to Bloomberg’s reporting.
Abdullah told the briefing GSK is assembling a franchise of lung cancer drugs, with additional medicines in development for blood and gastrointestinal cancers. Lung cancer is one of the largest segments of the global oncology market, generating billions of dollars in annual drug sales, Reuters noted.
Where Nelkarmi fits against Alecensa and Lorbrena
Rivals already occupy the field. Reuters reported the new drug will compete against Roche’s Alecensa — the most commonly used first-line ALK treatment — and Pfizer’s Lorbrena. Both target the same ALK mutation, and both were approved for earlier lines of treatment than Nelkarmi’s label covers.
🔎 🚨FDA APPROVAL: The #FDA granted accelerated approval to neladalkib (NelkarmI) for ALK+ #NSCLC, indicated in second line after alectinib or after2 prior ALK TKIs and platinum-based chemotherapy. Read more: https://t.co/rwgTS8HtQj
| Drug | Manufacturer | Target | Approved use (per sources) |
|---|---|---|---|
| Alecensa (alectinib) | Roche | ALK | Most common first-line ALK treatment |
| Lorbrena (lorlatinib) | Pfizer | ALK | Targets the ALK mutation |
| Nelkarmi (neladalkib) | GSK | ALK | After alectinib, or two or more prior ALK inhibitors plus platinum chemotherapy |
| Jideytro | GSK | ROS1 | ROS1-positive NSCLC after a prior ROS1 inhibitor |
Nelkarmi’s place in first-line care is unresolved. Reuters reported the drug is being studied against Alecensa in a late-stage trial to establish how effective it will be as a first-line treatment — the same trial mentioned by Bloomberg meant to establish how much the drug ultimately helps patients.
According to the American Cancer Society, about 229,410 people in the United States are expected to be diagnosed with lung cancer in 2026, making it the second most common cancer among both men and women.
For patients outside the US, access depends on regional regulators. Health systems including the NHS would need both their regulator's approval and a payer decision before the drug reaches local clinics.
Contraindications & When to Consult a Doctor
It is not approved for newly diagnosed patients, and molecular testing confirming the ALK rearrangement is required before eligibility can be assessed. Accelerated approval also means the safety picture rests on early-phase data; the FDA's own listing of the decision notes ongoing trials.
Patients currently on ALK therapy should discuss with their oncologist before any change — sources here carry no dosing, side-effect frequency, or discontinuation guidance, and those decisions belong with the treating physician using the full prescribing information.
The trajectory now sits with the confirmatory trial.
References
- US Food and Drug Administration — Hematology/Oncology (Cancer) Approvals & Safety Notifications
- Financial Times — GSK wins US approval for second lung cancer drug from $10.6bn Nuvalent deal
- Quartz — GSK won U.S. approval for its second lung cancer drug from the Nuvalent deal (citing Bloomberg and Reuters)
- Reuters (via KWSN) — US FDA approves GSK’s second lung cancer drug from historic $11 billion deal
- American Cancer Society — lung cancer incidence estimate for 2026